Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
17 results
Search Results
Now showing 1 - 10 of 17
Publication Metadata only Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres(2021) SALMAN, ANDAÇ; Can, P. K.; Salman, A.; Hoşgören-Tekin, S.; Kocatürk, E.Publication Metadata only What determines the treatment persistence in paediatric psoriasis?(WILEY, 2021) SALMAN, ANDAÇ; Salman, A.Publication Open Access Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic: Insights from Google Trends(WILEY, 2021-03) SALMAN, ANDAÇ; Esen-Salman, Kubra; Akin-cakici, Ozlem; Kardes, Sinan; Salman, AndacCoronavirus disease 2019 (COVID-19) pandemic had substantial effect both on daily life and medical practice. Internet data have been used to analyze the trends in public interest in various medical conditions and treatments. The aim of this study is to analyze the public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID-19 pandemic. Google Trends was queried for a total of 120 dermatological search queries. Three periods of 2020 ([March 15-May 9], [May 10-July 4], and [July 5-October 31]) were compared with the previous 4 years (2016-2019). A significantly decreased interest in skin cancers and certain dermatologic conditions (eg, pityriasis rosea and scabies) was observed throughout the study period. Whereas a significant increase of interest in dry skin, hair shedding, oily hair, atopic dermatitis, and hand eczema was detected during the study. An initial decrease in interest was followed by a significant increase for acne, comedones, melasma, rosacea, botox, dermaroller, and peeling. The study demonstrated a significant impact of the COVID-19 pandemic on the public interest in dermatology. The present results would help to create healthcare policies and information sources, which can meet the public demand. The reasons for the observed trends and their effect on patient outcomes might be of interest for future studies.Publication Open Access Phacomatosis pigmentokeratotica associated with unilateral toe walking due to short achilles tendon(WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020) SALMAN, ANDAÇ; Salman, Andac; Yucelten, Ayse Deniz; Cakici, Ozlem Akin; Unver, OlcayPhacomatosis pigmentokeratotica (PPK) is characterized by the co-occurrence of speckled lentiginous nevus (nevus spilus) and an organoid nevus with or without extracutaneous involvement. The extracutaneous manifestations may vary widely with musculoskeletal, neurologic, ocular, and vascular findings. The PPK is also associated with an increased risk of cutaneous or extracutaneous tumors. Therefore, the patients with PPK should be followed up regularly for possible malignant transformation. Here, we report a 5-year-old boy with PPK associated with toe walking due to short Achilles tendon, which was not previously reported, to our knowledge.Publication Open Access Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings(2022-11-01) SALMAN, ANDAÇ; Çakıcı Ö. A. , GUDER S., SALMAN A., Ergun T.Publication Metadata only Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data(WILEY, 2021) SALMAN, ANDAÇ; Salman, Andac; Aktas, Meryem; Sengun, Ozlem AptiOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.Publication Open Access Comment on Cling film for mobile phones to prevent cross-infection during the COVID-19 pandemic''(MOSBY-ELSEVIER, 2021-01) SALMAN, ANDAÇ; Salman, Andac; Comert-Ozer, Elif; Esen-Salman, KubraPublication Open Access Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology(DERI ZUHREVI HASTALIKLAR DERNEGI, 2020-06-29) SALMAN, ANDAÇ; Salman, Andac; Alper, Sibel; Atakan, Nilgun; Baskan, Emel Bulbul; Borlu, Murat; Canpolat, Filiz; Erdem, Teoman; Erdem, Yasemin; Gul, Ulker; Kartal, Selda Pelin; Koca, Rafet; Kucuk, Ozlem Su; Ogretmen, Zerrin; Ozkaya, Esen; Saricaoglu, Hayriye; Savk, Ekin; Taskapan, Oktay; Utas, Serap; Kocaturk, EmekPublication Metadata only Yellow Urticaria(ELSEVIER, 2021) SALMAN, ANDAÇ; Cakici, Ozlem Akin; Sengun, Ozlem Apti; Tekin, Selcen Hosgoren; Salman, AndacPublication Open Access Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature(BILIMSEL TIP YAYINEVI, 2021-08-23) SALMAN, ANDAÇ; Salman, Andac; Aktas, MeryemOmalizumab is a safe and effective treatment option for chronic spontaneous urticaria (CSU). Although cohort studies in patients with asthma show no increased risk of congenital abnormalities, very little data exist in the literature regarding the use of omalizumab for CSU during pregnancy. Herein, the safe and successful use of omalizumab updosing in a pregnant woman with CSU along with a review of the published literature is presented.